Current primary open-angle glaucoma treatments and future directions

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1699-1707

  Beidoe, Gabriel ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Betaxolol; Bis(7) tacrine; Memantine; Mirtogenol; POAG; Timolol; Travoprost

Indexed keywords

ACETYLCYSTEINE; AGENTS ACTING ON THE EYE; ALPHA TOCOPHEROL; ANTIGLAUCOMA AGENT; BETAXOLOL; BIMATOPROST; BIS(7)TACRINE; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; CANNABINOID; CANNABIS; CARTEOLOL; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; DRONABINOL; ERYTHROPOIETIN; FORSKOLIN; LATANOPROST; LATANOPROST PLUS TIMOLOL; MEMANTINE; MIRTOGENOL; NIMODIPINE; PILOCARPINE; PLACEBO; RUTOSIDE; THIAMINE; TIMOLOL; TIMOLOL PLUS TRAVOPROST; UNCLASSIFIED DRUG;

BLURRED VISION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EYE EXAMINATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LUNG DISEASE; MONOTHERAPY; MORNING DOSAGE; NONHUMAN; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PRESSURE MEASUREMENT; REVIEW; RISK FACTOR;

EID: 84869229335     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S32933     Document Type: Review

References (67)

1. Monemi S, Spaeth G, DaSilva A, et al. Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. Hum Mol Genet. 2005;14(6):725-733.
2. Tamura H, Kawakami H, Kanamoto T, et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci. 2006;246(1-2):79-83.
3. Vyas P, Naik U, Gangaiah JB. Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360degrees synechial angle-closure glaucoma: a preliminary study. Indian J Ophthalmol. 2011;59(1):13-16.
4. NEI. Glaucoma and Optic Neuropathies Program. [Web page] Bethesda, MD: National Eye Institute; 2009 [updated 2009]. Available from: http://www.nei.nih.gov/strategicplanning/nationalplan1.pdf. Accessed March 3, 2011.
5. Dipiro J, Talbert RL, Yee GC, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw Hill; 2009.
6. Heiting G, Haddrill M. Glaucoma: Types, Symptoms, Diagnosis and Treatment [updated Dec, 2011]; Available from: http://www.allaboutvision.com/conditions/glaucoma.htm#typesofglaucoma. Accessed June 6, 2012.
7. Park BC, Tibudan M, Samaraweera M, Shen X, Yue BY. Interaction between two glaucoma genes, optineurin and myocilin. Genes Cells. 2007;12(8):969-979.
8. Musch DC, Gillespie BW, Niziol LM, Cashwell LF, Lichter PR. Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2008;115(6):927-933.
9. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10): 1268-1279.
10. AAO. American Academy of Ophthalmology Glaucoma Panel, Primary Open Angle Glaucoma. [Web page] San Francisco, CA: AAO PPP Glaucoma Panel, Hoskins Center for Quality Eye Care; 2010; Available from: http://www.aao.org/ppp. Accessed March 3, 2011.
11. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943-1953.
12. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
13. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991; 109(8):1090-1095.
14. Gogate P, Deshpande R, Chelerkar V, Deshpande S, Deshpande M. Is glaucoma blindness a disease of deprivation and ignorance? A case-control study for late presentation of glaucoma in India. Indian J Ophthalmol. 2011;59(1):29-35.
15. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol. 2002;133(1): 135-137.
16. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol. 2002;47(3):165-168.
17. GRF. Glaucoma Research Foundation. [Website] San Francisco: Glaucoma Research Foundation; [updated May 1, 2009]; Available from: http://www.glaucoma.org/learn/diagnostic_test.php. Accessed February 25, 2011.
18. Narayanaswamy A, Neog A, Baskaran M, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55(2):127-131.
19. Katzung BG. Basic and Clinical Pharmacology. 7th ed. Norwalk, CT: Appleton and Lange; 1997.
20. Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28(3):332-339.
21. Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002;37(1):21-26.
22. Kerr CR, Hass I, Drance SM, Walters MB, Schulzer M. Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma. Br J Ophthalmol. 1982;66(2): 109-114.
23. Diggory P, Cassels-Brown A, Vail A, Hillman JS. Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol. 1998;82(2):146-149.
24. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology. 2000;107(6):1171-1177.
25. Clinical Pharmacology. Drug Monographs. [Web database]: Clinical Pharmacology; [updated 2009-2010]; Available from: http://www.clinicalpharmacology-ip.com/default.aspx. Accessed March 3, 2011.
26. Micromedex. Drug Monograph. [Web database]: Micromedex; [updated 2011]; Available from: http://www.thomsonhc.com. Accessed March 3, 2011.
27. Kammer JA, Katzman B, Ackerman SL, Hollander DA. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. Br J Ophthalmol. 2010;94(1):74-79.
28. Denis P, Baudouin C, Bron A, et al. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010;10:4.
29. Ang A, Reddy MA, Shepstone L, Broadway DC. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol. 2004;88(5):630-634.
30. Stankiewicz A, Wierzbowska J, Siemiatkowska A, et al. The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma. Br J Ophthalmol. 2010;94(10):1307-1311.
31. Mansberger SL, Hughes BA, Gordon MO, et al. comparison of initial intraocular pressure response with topical β-adrenergic antagonists and prostaglandin analogues in African American and White individuals in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2007;125(4):454-459.
32. Watson PG, Barnett MF, Parker V, Haybittle J. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol. 2001;85(8):962-968.
33. Robin AL. Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. Trans Am Ophthalmol Soc. 1996;94:89-101; discussion 101-103.
34. Suzuki Y, Iwase A, Araie M, et al. Risk factors for open-angle glaucoma in a Japanese population: the Tajimi Study. Ophthalmology. 2006;113(9):1613-1617.
35. Mitchell P, Hourihan F, Sandbach J, Wang JJ. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology. 1999;106(10):2010-2015.
36. Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010;128(2): 165-172.
37. Sellem E, Rouland JF, Baudouin C, et al. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination. BMC Ophthalmol. 2010;10:10.
38. Martinez A, Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharmacol Ther. 2009;25(3):239-248.
39. Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma. 2007;16(4):352-357.
40. Kimal Arici M, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22(1):37-42.
41. Maruyama K, Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma. 2006;15(4):341-345.
42. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120(10):1286-1293.
43. Rhee DJ, Peace JH, Mallick S, Landry TA, Bergamini MV. A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2(2):313-319.
44. Doi LM, Melo LA Jr, Prata JA Jr. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial. Br J Ophthalmol. 2005; 89(5):547-549.
45. Dapling RB, Cunliffe IA, Longstaff S. Influence of apraclonidine and pilocarpine alone and in combination on post laser trabeculoplasty pressure rise. Br J Ophthalmol. 1994;78(1):30-32.
46. Parrish RK, Feuer WJ, Schiffman JC, Lichter PR, Musch DC. Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. Am J Ophthalmol. 2009;147(4):717-724. e711.
47. Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci. 2008;85(6):406-416.
48. Steigerwalt RD, Gianni B, Paolo M, Bombardelli E, Burki C, Schonlau F. Effects of Mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects. Mol Vis. 2008;14:1288-1292.
49. He Y, Leung KW, Zhang YH, et al. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Invest Ophthalmol Vis Sci. 2008;49(4):1447-1458.
50. University of Roma La Sapienza. Retinal nerve fibres layers thickness study in glaucomatous patients. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated December 3, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT01254006?term=NCT01254006&rank=1. NLM identifier: NCT01254006. Accessed March 3, 2011.
51. Future Products Management. Treatment of glaucomatous neuropathy with food additives. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2005 [updated March 10, 2009]. Available from: http://clinicaltrials.gov/ct2/show/NCT00196677?term=NCT00196677&rank=1. NLM identifier: NCT00196677. Accessed March 3, 2011.
52. Sooft Italia. Effects of the oral administration of an association of forskolin with rutin and vitamins B on intraocular pressure in patients affected by primary open angle glaucoma and treated with either beta-blockers or prostaglandin eye drops. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2009 [updated June 5, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00863811?term=NCT00863811.&rank=1. NLM identifier: NCT00863811. Accessed March 30, 2011.
53. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007;48(3):1212-1218.
54. Zhan GL, Camras CB, Palmberg PF, Toris CB. Effects of marijuana on aqueous humor dynamics in a glaucoma patient. J Glaucoma. 2005;14(2):175-177.
55. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349-353.
56. Fang JH, Wang XH, Xu ZR, Jiang FG. Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage. BMC Neurosci. 2010;11:31.
57. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37(8):1618-1624.
58. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114(3):299-305.
59. Yucel YH, Gupta N, Zhang Q, Mizisin AP, Kalichman MW, Weinreb RN. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol. 2006;124(2): 217-225.
60. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009;87(4):450-454.
61. Ko ML, Peng PH, Hsu SY, Chen CF. Dietary deficiency of vitamin E aggravates retinal ganglion cell death in experimental glaucoma of rats. C Eye R. 2010;35(9):842-849.
62. Roh YJ, Moon C, Kim SY, Park MH, Bae YC, Chun MH, et al. Glutathione depletion induces differential apoptosis in cells of mouse retina, in vivo. Neurosci Lett. 2007;417(3):266-270.
63. The Catholic University of Korea. Evaluation of systemic glutathione level in patients with normal tension glaucoma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2007 [updated June 14, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00570362?term=NCT00570362&rank=1. NLM identifier: NCT00570362. Accessed March 3, 2011.
64. Luksch A, Rainer G, Koyuncu D, et al. Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. Br J Ophthalmol. 2005;89(1):21-25.
65. Piltz JR, Bose S, Lanchoney D. The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects. J Glaucoma. 1998;7(5):336-342.
66. Harris A, Evans DW, Cantor LB, Martin B. Hemodynamic and visual function effects of oral nifedipine in patients with normal-tension glaucoma. Am J Ophthalmol. 1997;124(3):296-302.
67. Cellini M, Possati GL, Caramazza N, Profazio V, Caramazza R. The use of flunarizine in the management of low-tension glaucoma: a color Doppler study. Acta Ophthalmol Scand Suppl. 1997;224:57-58.